Biogen develops market and manufacture therapies for people living with serious neurological, autoimmune and hematologic disorders. Founded in 1978 by a small group of visionary scientists, Biogen helped pioneer the biotechnology industry. Today, it is one of the oldest independent biotechnology companies in the world.
Biogen Idec helps to create a new research consortium to identify new approaches to treating amyotrophic lateral sclerosis (ALS). Biogen Idec collaborates with the National Hemophilia Foundation, the American Thrombosis and Hemostasis Network, and the Puget Sound Blood Center on a nationwide program that offers free genetic testing to people with hemophilia and their families. It announced a collaboration with Isis Pharmaceuticals to identify new approaches in treating spinal muscular atrophy (SMA), myotonic dystrophy type 1 and neurological/neuromuscular disorders. The company acquires Stromedix, a biotechnology company focused on innovative therapies for fibrosis and organ failure.
It applies innovative approaches, leading-edge science and world-class technical capabilities to its pursuit of medicines that improve the lives of patients. Its Research and Development efforts are primarily focused on three areas in which it is recognized leaders:
· Neurology
· Hematology
· Immunology
Biogen develops and provide therapies to people living with serious diseases, like multiple sclerosis and hemophilia. It develops medicines for serious medical conditions with few or no treatment options. Every day, it works to bring patients better outcomes and advance their standard of care.
Multiple Sclerosis
· AVONEX
· FAMPYRA
· PLEGRIDY
· TECFIDERA
· TYSABRI
Hemophilia
· ALPROLIX
· ELOCTATE
Partnered Therapies
· GAZYVA
· RITUXAN
Explore career opportunities at Biogen, and experience the fulfillment that comes from helping to discover, manufacture and market new treatments for patients.
Connect with Biogen for your next temp job. OnContracting can help you connect with its preferred staffing agencies.
